Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit

Methodist Health System132 enrolled

Overview

Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.

Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP. Patients with respiratory culture data signifying a Gram-negative organism as the cause of HAP/VAP will be analyzed as described below if study inclusion criteria is met. Minimum inhibitory concentration (MIC) data will interpreted per Clinical \& Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance. Multivariable logistic regression will be performed to determine risk factors for piperacillin-tazobactam, cefepime or meropenem resistant Gram-negative isolates. Project target date of completion and close-out is May 2021.

Study Type

OBSERVATIONAL

Enrollment

132

Conditions

Ventilator-associated Pneumonia Hospital-acquired Pneumonia

Interventions

ObservationalOTHER

Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ICU, Neuro critical care unit admission * Diagnosis of HAP or VAP * Respiratory culture positive for Gram-negative organism Exclusion Criteria: * ICU length of stay \<48 hours prior to HAP/VAP * Culture or MIC data unavailable * Pregnant

Locations (1)

Methodist Dallas Medical Center

Dallas, Texas, United States